多西紫杉醇联合顺铂治疗37例晚期非小细胞肺癌临床分析

目的 观察多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应.方法 37例经病理和(或)细胞学证实为晚期非小细胞肺癌患者,予多西紫杉醇75mg/m2,静滴60min d1;DDP25～30mg/m2,静滴,d1-3.21d为1周期,2周期为1个疗程.结果 全组无CR病例,PR 16例,SD 17例,PD 4例,总有效率43.2%,中位生存期11.3个月,1年生存率40.5%.不良反应:主要以骨髓抑制及消化道反应.结论 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效较好,不良反应可耐受.

Clinical analysis on combined docetaxel and cisplatin for advanced non-small-cell lung cancer in 37 cases

Objective To observe the efficiency and toxicity of the combination of docetaxel and cisplatin in the treatment of advanced non-small-cell lung cancer.Methods Thirty-seven patients with advanced non-small-cell lung cancer confirmed by tissue pathology and/or cytopathology,were administered with docetaxel 75mg/m2,intravenous d1,cisplantin 25-30mg/m2,intravenous d1-d3,every 21d was one cycle and two cycles were one course of treatment.Results There were no case of CR,16 cases of PR,17 cases of SD and 4 cases of PD.The total response rate was 43.2%,the median survival time 11.3 months,one year survival rate 40.5%.The major side effect and toxicity were bone marrow suppression and digestive reactions.Conclusion The combination of docetaxel and cisplatin has a good response in the treatment of advanced non-small-cell lung cancer,the side effect and toxicity are tolerable.